Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Aug 1;80(8):798-804.
doi: 10.1001/jamaneurol.2023.1408.

The Semont-Plus Maneuver or the Epley Maneuver in Posterior Canal Benign Paroxysmal Positional Vertigo: A Randomized Clinical Study

Affiliations
Randomized Controlled Trial

The Semont-Plus Maneuver or the Epley Maneuver in Posterior Canal Benign Paroxysmal Positional Vertigo: A Randomized Clinical Study

Michael Strupp et al. JAMA Neurol. .

Abstract

Importance: Questions remain concerning treatment efficacy for the common condition of benign paroxysmal positional vertigo (BPPV).

Objective: To compare the effectiveness of the Semont-plus maneuver (SM-plus) and the Epley maneuver (EM) for treatment of posterior canal benign paroxysmal positional vertigo (pcBPPV) canalolithiasis.

Design, setting, and participants: This prospective randomized clinical trial was performed at 3 national referral centers (in Munich, Germany; Siena, Italy; and Bruges, Belgium) over 2 years, with a follow-up to 4 weeks after the initial examination. Recruitment took place from June 1, 2020, until March 10, 2022. Patients were selected randomly during routine outpatient care after being referred to 1 of the 3 centers. Two hundred fifty-three patients were assessed for eligibility. After consideration of the exclusion criteria as well as informed consent, 56 patients were excluded and 2 declined to participate, with 195 participants included in the final analysis. The analysis was prespecified and per-protocol.

Interventions: After being randomized to the SM-plus or the EM group, patients received 1 initial maneuver from a physician, then subsequently performed self-maneuvers at home 3 times in the morning, 3 times at noon, and 3 times in the evening.

Main outcome and measures: Patients had to document whether they could provoke positional vertigo every morning. The primary end point was the number of days until no positional vertigo could be induced on 3 consecutive mornings. The secondary end point was the effect of the single maneuver performed by the physician.

Results: Of the 195 participants included in the analysis, the mean (SD) age was 62.6 (13.9) years, and 125 (64.1%) were women. The mean (SD) time until no positional vertigo attacks could be induced in the SM-plus group was 2.0 (1.6) days (median, 1 [range, 1-8] day; 95% CI, 1.64-2.28 days); in the EM group, 3.3 (3.6) days (median, 2 [range, 1-20] days; 95% CI, 2.62-4.06 days) (P = .01; α = .05, 2-tailed Mann-Whitney test). For the secondary end point (effect of a single maneuver), no significant difference was detected (67 of 98 [68.4%] vs 61 of 97 [62.9%]; P = .42; α = .05). No serious adverse event was detected with both maneuvers. Nineteen patients (19.6%) in the EM group and 24 (24.5%) in the SM-plus group experienced relevant nausea.

Conclusions and relevance: The SM-plus self-maneuver is superior to the EM self-maneuver in terms of the number of days until recovery in pcBPPV.

Trial registration: ClinicalTrials.gov Identifier: NCT05853328.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Strupp reported serving as joint chief editor of the Journal of Neurology, editor in chief of Frontiers of Neuro-otology, and section editor of F1000Research; receiving speaker’s honoraria from Abbott Laboratories, Actelion, Auris Medical, Biogen Inc, Eisai Co, Ltd, Grünenthal, GSK PLC, Hennig Arzneimittel GmbH & Co KG, Interacoustics, Johnson & Johnson, Merck & Co Inc, Neuro Update, Otometrics, Laboratoires Pierre Fabre, Teva Pharmaceutical Industries Ltd, UCB, and Viatris Inc; being a shareholder, investor, and chief medical officer of IntraBio; being the distributor of the M-glasses and Positional Vertigo app; receiving support for clinical studies from Decibel Therapeutics, Cures Within Reach, and Heel; and consulting for Abbott Laboratories, Actelion, Auris Medical, Bulbitec AS, Heel, IntraBio, Sensorion, and Vertify. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Schematic Drawing of the Movement of the Otoconia of the Semont-plus Maneuver and Epley Maneuver for Benign Paroxysmal Positional Vertigo of the Left Posterior Canal
A, The Semont-plus maneuver includes the upright position with (1) turning of the head by 45° toward the nonaffected side; (2) movement of the body by 150° toward the affected side, which moves the otoconia further in the direction in which they should move (A toward B); (3) and since the clot is beyond the vertex (B toward C), the movement of body by 240° moves the clot into the direction (4) of the vestibulum (position D of the otoconia). B, The Epley maneuver includes upright position and (1) rotation of the head 45° toward the affected ear; (2) movement of the body backward so that the head is in a hanging position below the earth horizontal; (3) rotation of the head 90° toward the nonaffected ear; (4) rotation of the whole body downward so that the patient faces the floor and their affected ear is pointing toward the ceiling; and (5) going into the upright position while keeping a rotation of the head 45° toward the nonaffected ear, and turning the head back to the neutral position at the end. A indicates anterior semicircular canal; H, horizontal semicircular canal; and P, posterior semicircular canal.
Figure 2.
Figure 2.. Study Flowchart
Figure 3.
Figure 3.. Primary End Point
Histogram of days until no positional vertigo could be induced with the Semont-plus maneuver and Epley maneuver.

Similar articles

Cited by

References

    1. von Brevern M, Bertholon P, Brandt T, et al. . Benign paroxysmal positional vertigo: diagnostic criteria. J Vestib Res. 2015;25(3-4):105-117. doi:10.3233/VES-150553 - DOI - PubMed
    1. Brandt T, Steddin S, Daroff RB. Therapy for benign paroxysmal positioning vertigo, revisited. Neurology. 1994;44(5):796-800. doi:10.1212/WNL.44.5.796 - DOI - PubMed
    1. Korres S, Balatsouras DG, Kaberos A, Economou C, Kandiloros D, Ferekidis E. Occurrence of semicircular canal involvement in benign paroxysmal positional vertigo. Otol Neurotol. 2002;23(6):926-932. doi:10.1097/00129492-200211000-00019 - DOI - PubMed
    1. Moon SY, Kim JS, Kim BK, et al. . Clinical characteristics of benign paroxysmal positional vertigo in Korea: a multicenter study. J Korean Med Sci. 2006;21(3):539-543. doi:10.3346/jkms.2006.21.3.539 - DOI - PMC - PubMed
    1. Epley JM. The canalith repositioning procedure: for treatment of benign paroxysmal positional vertigo. Otolaryngol Head Neck Surg. 1992;107(3):399-404. doi:10.1177/019459989210700310 - DOI - PubMed

Publication types

Associated data